Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States

Fasching P, Huang M, Haiderali A, Xue W, Pan W, Zhou ZY, Hu P, Chaudhuri M, De Tilleghem CLB, Cappoen N, O'Shaughnessy J (2022)

Publication Type: Conference contribution

Publication year: 2022

Journal

Annals of Oncology Elsevier

Publisher: ELSEVIER

City/Town: AMSTERDAM

Pages Range: S170-S171

Conference Proceedings Title: ANNALS OF ONCOLOGY

DOI: 10.1016/j.annonc.2022.03.115

Authors with CRIS profile

Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe

Involved external institutions

Merck & Co., Inc. / Merck Sharp & Dohme Corp (MSD) US United States (USA) (US) Analysis Group Ltd GB United Kingdom (GB) Complete Health Economics Outcomes and Research Solutions (CHEORS) US United States (USA) (US) Baylor University (BU) US United States (USA) (US)

How to cite

APA:

Fasching, P., Huang, M., Haiderali, A., Xue, W., Pan, W., Zhou, Z.-Y.,... O'Shaughnessy, J. (2022). Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States. In ANNALS OF ONCOLOGY (pp. S170-S171). AMSTERDAM: ELSEVIER.

MLA:

Fasching, Peter, et al. "Cost effectiveness of pembrolizumab in combination with chemotherapy as neoadjuvant therapy and continued as a single agent as adjuvant therapy for high-risk early-stage TNBC in the United States." Proceedings of the ANNALS OF ONCOLOGY AMSTERDAM: ELSEVIER, 2022. S170-S171.

BibTeX: Download